| 摘要 |
New pharmaceutical formulations contain a thieno (2,3-d) pyrimidine derivative PDE V inhibitor (I) and an antithrombotic agent (II), a calcium antagonist (III) or a prostaglandin or its derivative (IV). New pharmaceutical formulations contain at least one of thieno (2,3-d) pyrimidine derivative PDE V inhibitors of formula (I) and their salts and/or solvates, and at least one antithrombotic agent (II), calcium antagonist(s) (III) or prostaglandin(s) or their derivative(s) (IV). R1, R2 = H, A or hamn lo, but not both H; or R1 + R2 = 3-5C alkylene; R3, R4 = H, A, OH, OA or halo; or R3 + R4 = 3-5C alkylene, OCH2CH2, OCH2O or OCH2CH2O; X = R5 or R6, both monosubstituted by R7; R5 = 1-10C alkylene (optionally having one or two CH2 groups replaced by CH=CH) or -C6H4-(CH2)m-; R6 = 6-12C cycloalkylalkylene; R7 = COOH, COOA, CONH2, CONHA, CON(A)2 or CN; A = 1-6C alkyl; m = 1 or 2; and n = 0-3. Independent claims are also included for: (1) the use of 5-(4-(3-chloro-4-methoxy-benzylamino)-4,5,6,7-tetrahydro-(1)-benzothieno (2,3-d) pyrimidin-2-yl)-valeric acid (Ia) as the ethanolamine salt for the production of a medicament for treating pulmonary hypertension, congestive heart failure, chronic obstructive pulmonary disease, cor pulmonale and/or right cardiac insufficiency; and (2) kits including (Ia) ethanolamine salt and (II), (III) or (IV) in separate packaging.
|
